Race updates its Three Pillar Strategy, detailing intended programs and activitiesThe update confirms progress on all Three Pillars, and shares concrete steps towards increasing value for Bisantrene, through its application…

Race enters a collaborative preclinical research program with The University of Newcastle to support the use of Bisantrene in the treatment of extramedullary acute myeloid leukaemia (AML)Research designed to support…

Race enters a collaborative preclinical research program with The University of Newcastle to explore use of Bisantrene as a novel FTO-directed treatment for clear cell renal cell carcinoma (ccRCC)Research designed…

Race enters collaborative preclinical research program with The University of Newcastle to explore use of Bisantrene as a novel FTO directed treatment for melanomaResearch designed to identify drug combinations that…

Race Oncology Limited (ASX: RAC) is pleased to share the final results of our collaborative preclinical research program with the eminent cancer researcher, Associate Professor Nikki Verrills of The University…